Table of Content



Chapter 1 The U.S. Platelet Rich Plasma (PRP) Market: Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and forecast timeline
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased database
1.4.2 GVR’sinternal database
1.4.3 Secondary sources
1.4.4 Primary research
1.4.5 Details of primary research
1.5 Information or Data Analysis
1.5.1 The U.S. platelet rich plasma (PRP) market: Segment revenue and growth analysis
1.5.2 Data analysis models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity flow analysis
1.7.1.1 Approach 1: Commodity flow approach
1.7.1.2 Approach 2: Country-wise market estimation using bottom up approach
1.8 The U.S. Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
Chapter 2 The U.S. Platelet Rich Plasma (PRP) Market: Executive Summary
2.1 Market Outlook
2.2 Competition Milieu
2.3 Segment Outlook
2.4 Market Summary, 2019 (USD Million)
Chapter 3 The U.S. Platelet Rich Plasma (PRP) Market: Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 Parent Market Lineage
3.3 Market Dynamics
3.3.1 Market drivers analysis
3.3.1.1 Rise in the incidence of orthopedic disorders and sports injuries
3.3.1.2 Increasing number of cosmetic surgery procedures
3.3.1.3 Extending medical applications of platelet rich plasma
3.3.2 Market restraint analysis
3.3.2.1 High costs associated with PRP products
3.4 Penetration & Growth Prospect Mapping, by Application, 2019
Chapter 4 The U.S. Platelet Rich Plasma (PRP) Market: Business Environment Analysis
4.1 SWOT Analysis; by Factor (Political & Legal, Economic and Technological)
4.2 Porter’s Five Forces Analysis
Chapter 5 The U.S. Platelet Rich Plasma (PRP) Market: Type Business Analysis
5.1 The U.S. Platelet Rich Plasma (PRP) Market: Type Movement Analysis
5.2 Pure PRP
5.2.1 The U.S. pure PRP market estimates and forecast, 2016 - 2027 (USD Million)
5.3 Leukocyte Rich PRP
5.3.1 The U.S. leukocyte rich PRP market estimates and forecast, 2016 - 2027 (USD Million)
5.4 Others
5.4.1 The U.S. PRP market estimates and forecast for others, 2016 - 2027 (USD Million)
Chapter 6 The U.S. Platelet Rich Plasma (PRP) Market: Application Business Analysis
6.1 Orthopedics
6.1.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for orthopedics, 2016 - 2027 (USD Million)
6.2 Sports Medicine
6.2.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for sports medicine, 2016 - 2027 (USD Million)
6.2.2 PRP injections
6.2.2.1 The U.S. platelet rich plasma (PRP) injections market estimates and forecast for sports medicine, 2016 - 2027 (USD Million)
6.2.3 PRP kits
6.2.3.1 The U.S. platelet rich plasma (PRP) kits market estimates and forecast for sports medicine, 2016 - 2027 (USD Million)
6.2.4 PRP systems
6.2.4.1 The U.S. platelet rich plasma (PRP) systems market estimates and forecast for sports medicine, 2016 - 2027 (USD Million)
6.3 Cosmetic Surgery and Dermatology
6.3.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for cosmetic surgery and dermatology, 2016 - 2027 (USD Million)
6.4 Ophthalmic Surgery
6.4.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for ophthalmic surgery, 2016 - 2027 (USD Million)
6.5 Neurosurgery
6.5.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for neurosurgery, 2016 - 2027 (USD MILLION)
6.6 General Surgery
6.6.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for general surgery, 2016 - 2027 (USD Million)
6.7 Others
6.7.1 The U.S. platelet rich plasma (PRP) market estimates and forecast for others, 2016 - 2027 (USD Million)
Chapter 7 U.S. Platelet Rich Plasma (PRP) Market: End-Use Business Analysis
7.1 The U.S. Platelet Rich Plasma (PRP) Market: End-use Movement Analysis
7.2 Hospitals
7.2.1 The U.S. platelet rich plasma (PRP) market for hospitals, 2016 - 2027 (USD Million)
7.3 Clinics
7.3.1 The U.S. platelet rich plasma (PRP) market for clinics, 2016 - 2027 (USD Million)
7.4 Others
7.4.1 The U.S. platelet rich plasma (PRP) market for others, 2016 - 2027 (USD Million)
Chapter 8 The U.S. Platelet Rich Plasma (PRP) Market: Company Profile
8.1 Strategy Framework
8.2 Market Participation Categorization
8.3 Company Profiles
8.3.1 Johnson & Johnson
8.3.1.1 Company overview
8.3.1.2 DePuy Synthes
8.3.1.2.1 Company overview
8.3.1.3 Financial performance
8.3.1.4 Product benchmarking
8.3.1.5 Strategic initiatives
8.3.2 Arthrex, Inc.
8.3.2.1 Company overview
8.3.2.3 Financial performance
8.3.2.4 Product benchmarking
8.3.2.5 Strategic initiatives
8.3.3 EmCyte Corporation
8.3.3.1 Company overview
8.3.3.2 Financial performance
8.3.3.3 Product benchmarking
8.3.3.4 Strategic initiatives
8.3.4 DR. PRP America, LLC
8.3.4.1 Company overview
8.3.1.2 Financial performance
8.3.1.3 Product benchmarking
8.3.1.4 Strategic initiatives
8.3.5 Juventix
8.3.5.1 Company overview
8.3.5.2 Financial performance
8.3.5.3 Product benchmarking
8.3.5.4 Strategic initiatives
8.3.6 Terumo Corporation
8.3.6.1 Company overview
8.3.6.2 Terumo BCT, Inc.
8.3.6.2.1 Company overview
8.3.6.3 Financial performance
8.3.6.4 Product benchmarking
8.3.6.5 Strategic initiatives
8.3.7 Zimmer Biomet
8.3.7.1 Company overview
8.3.7.2 Financial performance
8.3.7.3 Product benchmarking
8.3.7.4 Strategic initiatives
8.3.8 Stryker
8.3.8.1 Company overview
8.3.8.2 Financial performance
8.3.8.3 Product benchmarking
8.3.8.4 Strategic initiatives



List of Tables



Table 1 List of secondary sources
Table 2 Growth factors involved in stages of wound healing
Table 3 Growth factors involved in wound healing with their origin
Table 4 Use of PRP in wound management
Table 5 Products and service providers: Knee OA injectable biologics
Table 6 Clinical trials performed until 2017 to supporting the data efficacy of biologics in sports medicine
Table 7 Manufacturers operating in the pure PRP market space